| Literature DB >> 34336733 |
Hengci Zhang1,2, Shiyuan Qiu1,3, Cheng Zhong1,2, Lin Shi1,2, Jiacheng Li1,2, Tao Zhang2,4, Xiaoping Zhu2,4, Mo Wang1,2.
Abstract
Background: Infection is the most common complication of Idiopathic Nephrotic Syndrome (INS) and the main cause of INS recurrence, severe infection and even leading to mortality. The purpose of this study was to investigate the risk factors of severe infection in INS children and the clinical parameters influencing prognosis.Entities:
Keywords: children; idiopathic nephrotic syndrome; prognosis; risk factor; severe infection
Year: 2021 PMID: 34336733 PMCID: PMC8316585 DOI: 10.3389/fped.2021.656215
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Relevant definitions in nephrotic syndrome.
| Relapse | Urine albumin 3+ or 4+ or proteinuria >40 mg/m 2 per h or urinary protein: creatinine ratio >2.0 (mg/mg) for 3 consecutive days |
| SSNS | Complete remission within 4 weeks of prednisone or prednisolone (PDN) at the standard dose (60 mg/m2/day or 2 mg/kg/day, maximum 60 mg/day) |
| SRNS | Persistent proteinuria despite 60 mg/m2 or 2 mg/kg for 8 weeks, after ensuring no infection or non-adherence to medication |
| SDNS | 2 consecutive relapses occurring while weaning to alternate-day steroids or within 2 weeks of steroid discontinuation |
SSNS, steroid-sensitive nephrotic syndrome; SRNS, steroid-resistant nephrotic syndrome; SDNS, steroid-dependent nephrotic syndrome.
General variables and definitions of severe infection.
| Fever (>38.5°C) |
| Hypothermia (<35°C) |
| Heart rate more than two SD above the normal value for age |
| Tachypnea (Respiratory rate higher than WHO classification for age) |
| Altered mental status |
| Leukocytosis (WBC count > 12,000 μL−1 or higher than the normal value for age) |
| Leukopenia (WBC count <4,000 μL−1 or below the normal value for age) |
| Plasma C-reactive protein more than two SD above the normal value |
| Plasma procalcitonin more than two SD above the normal value |
| Arterial hypotension (SBP less than two SD below normal value for age) |
| Arterial hypoxemia (PaO2/FiO2 <300) |
| Acute oliguria (urine output <0.5 mL kg−1 h−1 for at least 2 h despite adequate fluid resuscitation) |
| Coagulation abnormalities |
| Ileus (absent bowel sounds) |
| Hyperlactatemia (Lactate above upper limits laboratory normal) |
| Decreased capillary refill or mottling |
SD, standard deviation; WBC, white blood cell; SBP, systolic blood pressure; WHO, World Health Organization.
Figure 1Experimental design process.
Demographic characteristics, laboratory data of children with INS in the severe and non-severe infection group.
| Male | 73 (74.5%) | 98 | 38 (77.6%) | 49 | 0.166 | 0.684 |
| Female | 25 (25.5%) | 98 | 11 (22.4%) | 49 | ||
| Duration (months) | 0.37 (0.23, 1.78) | 98 | 3.00 (0.67, 12.00) | 49 | 0.000 | |
| Age (years) | 5.17 (2.52, 9.38) | 98 | 6.00 (2.67, 10.00) | 49 | 0.749 | |
| Initial episode | 68 (69.4%) | 98 | 18 (36.7%) | 49 | 14.347 | 0.000 |
| Relapse | 30 (30.6%) | 98 | 31 (63.3%) | 49 | ||
| SSNS | 82 (83.7%) | 98 | 19 (38.8%) | 49 | 32.434 | 0.000 |
| SRNS | 10 (10.2%) | 98 | 25 (51.0%) | 49 | ||
| SDNS | 6 (6.1%) | 98 | 5 (10.2%) | 49 | ||
| Duration of steroid (days) | 0 (0, 0) | 98 | 63 (0.362) | 49 | 0.000 | |
| MP pulse | 1 (1.0%) | 98 | 4 (8.2%) | 49 | 3.132 | 0.077 |
| <0.5 mg/kg | 82 (83.7%) | 98 | 26 (53.1%) | 49 | ||
| 0.5–1.5 mg/kg | 10 (10.2%) | 98 | 15 (30.6%) | 49 | 15.146 | 0.001 |
| >1.5 mg/kg | 6 (6.1%) | 98 | 8 (16.3%) | 49 | ||
| IS therapy ( | 4 (4.1%) | 98 | 18 (36.7%) | 49 | 27.369 | 0.000 |
| Duration of IS (days) | 0 (0, 0) | 98 | 0 (0, 11) | 49 | −5.141 | 0.000 |
| WBC (×109/L) | 10.18 (8.25, 12.13) | 98 | 13.25 (9.79, 17.34) | 49 | 0.000 | |
| ALC (×109/L) | 3.27 (2.23, 4.71) | 98 | 2.46 (1.56, 3.74) | 49 | 0.004 | |
| ANC (×109/L) | 5.46 (3.92, 8.58) | 98 | 9.99 (6.33, 12.33) | 49 | 0.000 | |
| PLT (×109/L) | 390.0 (313.5, 459.5) | 98 | 345.0 (244.0, 484.5) | 49 | 0.147 | |
| Hb (g/L) | 137 (125, 149) | 98 | 122 (96, 144) | 49 | 0.001 | |
| CRP ≥ 8 mg/L ( | 1 (1.0%) | 98 | 22 (44.9%) | 49 | 47.651 | 0.000 |
| PCT (ng/ml) | 0.05 (0.05, 0.10) | 85 | 0.65 (0.10, 11.29) | 46 | 0.000 | |
| Serum albumin (g/L) | 16.7 (14.7, 19.3) | 98 | 17.2 (13.4, 22.7) | 49 | 0.943 | |
| ALT (U/L) | 16.0 (10.4, 23.8) | 98 | 25.1 (14.8, 32.1) | 49 | 0.000 | |
| AST (U/L) | 33.3 (24.7, 43.2) | 98 | 31.2 (22.4, 51.3) | 49 | 0.578 | |
| ALP (U/L) | 163.6 (122.8, 199.3) | 98 | 101.6 (77.3, 139.3) | 49 | 0.000 | |
| Serum uric acid (μmol/L) | 326.5 (258.5, 374.0) | 98 | 360.0 (234.0, 506.2) | 49 | 0.009 | |
| Serum urea nitrogen (mmol/L) | 4.90 (3.78, 6.93) | 98 | 7.64 (4.21, 12.32) | 49 | 0.006 | |
| Serum creatinine (μmol/L) | 33.50 (25.68, 50.50) | 98 | 45.90 (29.35, 116.25) | 49 | 0.176 | |
| Serum potassium (mmol/L) | 4.50 ± 0.71 | 98 | 4.04 ± 0.72 | 49 | 0.000 | |
| Serum sodium (mmol/L) | 136.30 (132.55, 138.75) | 98 | 132.20 (128.95, 137.10) | 49 | 0.002 | |
| Serum chlorine (mmol/L) | 103.85 (100.20, 106.83) | 98 | 101.50 (96.50, 105.05) | 49 | 0.011 | |
| Serum calcium (mmol/L) | 1.94 (1.82, 2.05) | 98 | 1.87 (1.73, 2.09) | 49 | 0.145 | |
| Tch (mmol/L) | 10.76 ± 3.10 | 98 | 8.86 ± 3.53 | 49 | 0.001 | |
| Triglyceride (mmol/L) | 2.98 (2.01, 4.36) | 98 | 3.14 (2.43, 4.17) | 49 | 0.625 | |
| LDL (mmol/L) | 7.86 ± 2.96 | 98 | 5.66 ± 3.23 | 49 | 0.000 | |
| HDL (mmol/L) | 1.71 (1.23, 2.21) | 98 | 1.50 (0.81, 2.16) | 49 | 0.085 | |
| IgG (g/L) | 2.24 (1.36, 3.02) | 97 | 1.88 (0.83, 4.29) | 48 | 0.594 | |
| IgA (g/L) | 0.85 (0.63, 1.35) | 97 | 0.89 (0.62, 1.30) | 48 | 0.929 | |
| IgM (g/L) | 1.76 (1.31, 2.40) | 97 | 1.49 (1.09, 2.22) | 48 | 0.112 | |
| IgE (g/L) | 176.0 (46.2, 458.5) | 97 | 76.3 (23.8, 372.0) | 48 | 0.073 | |
| C3 (g/L) | 0.99 ± 0.21 | 97 | 0.85 ± 0.30 | 48 | 0.004 | |
| C4 (g/L) | 0.24 (0.19, 0.30) | 97 | 0.23 (0.17, 0.27) | 48 | 0.393 | |
| PT (s) | 10.4 (9.7, 11.1) | 87 | 11.2 (10.2, 13.3) | 48 | 0.002 | |
| APTT (s) | 31.00 (26.90, 35.70) | 87 | 36.75 (28.15, 53.23) | 48 | 0.004 | |
| Fib (g/L) | 5.97 ± 1.70 | 87 | 5.31 ± 2.02 | 48 | 0.045 | |
| D-dimer | 1.26 (0.58, 2.31) | 87 | 1.83 (0.69, 5.80) | 48 | 0.066 | |
p < 0.05,
p < 0.01.
Continuous parameters were expressed as (X̄ ± s) or P50 (P25, P75), and discrete parameters were expressed as a percentage (%). SIG, severe infection group; MP, methylprednisolone; IS, immunosuppressive; WBC, white blood cells; ALC, absolute lymphocyte count; ANC, absolute neutrophil count; PLT, platelets count; Hb, hemoglobin; CRP, C-reactive protein; PCT, procalcitonin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; Tch, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; PT, prothrombin time; APTT, activated partial thromboplastin time; Fib, fibrinogen.
Pathogen spectrum and the analysis in the severe and non-severe infection group.
| Gram-negative bacteria | 12 | 14 | 26 (56.52) | 2.577 | 0.108 |
| | 1 | 2 | 3 (6.52) | ||
| | 3 | 1 | 4 (8.70) | ||
| | 1 | 2 | 3 (6.52) | ||
| | 0 | 1 | 1 (2.17) | ||
| | 0 | 2 | 2 (4.35) | ||
| | 1 | 3 | 4 (8.70) | ||
| | 3 | 2 | 5 (10.87) | ||
| | 2 | 0 | 2 (4.35) | ||
| | 0 | 1 | 1 (2.17) | ||
| | 1 | 0 | 1 (2.17) | ||
| Gram-positive bacteria | 7 | 13 | 20 (43.48) | 10.256 | 0.001 |
| | 1 | 3 | 4 (8.70) | ||
| | 0 | 3 | 3 (6.52) | ||
| | 0 | 2 | 2 (4.35) | ||
| | 0 | 1 | 1 (2.17) | ||
| | 3 | 2 | 5 (10.87) | ||
| | 3 | 2 | 5 (10.87) | ||
| Fungus | 0 | 4 | 4 | 5.429 | 0.020 |
| Virus | 18 | 25 | 43 | ||
| | 8 | 5 | 13 (30.23) | 0.011 | 0.918 |
| | 2 | 2 | 4 (9.30) | 0.032 | 0.858 |
| | 1 | 0 | 1 (2.33) | 0.000 | 1.000 |
| | 3 | 7 | 10 (23.26) | 4.842 | 0.028 |
| | 3 | 3 | 6 (13.95) | 0.195 | 0.658 |
| | 1 | 8 | 9 (20.93) | 10.785 | 0.001 |
| Mycoplasma pneumoniae | 7 | 1 | 8 | 0.8100 | 0.368 |
Binary logistic regression analysis of risk factors of severe infections in children with INS.
| Steroid Combined with IS | 3.295 | 5.155 | 0.023 | 26.969 | 1.569 | 463.541 |
| SSNS | 9.375 | 0.009 | ||||
| SRNS | 4.607 | 8.886 | 0.003 | 100.191 | 4.845 | 2,071.880 |
| SDNS | 1.979 | 1.208 | 0.272 | 7.233 | 0.212 | 246.345 |
| Increased ALC | −1.033 | 10.025 | 0.002 | 0.356 | 0.188 | 0.675 |
| CRP ≥ 8 mg/L | 8.775 | 11.831 | 0.001 | 6,468.029 | 43.581 | 959,935.668 |
| Increased C3 | −8.205 | 5.405 | 0.020 | 0.000 | 0.000 | 0.276 |
| Infection with gram-positive bacteria | 8.933 | 9.662 | 0.002 | 7,580.545 | 27.126 | 2,118,452.938 |
| Infection with influenza virus | 4.240 | 6.243 | 0.012 | 69.426 | 2.494 | 1,932.221 |
| Infection with RSV | 5.868 | 7.301 | 0.007 | 353.681 | 5.011 | 24,963.819 |
| Constant | 3.318 | 1.269 | 0.260 | 27.612 | ||
IS, Immunosuppressant; ALC, absolute lymphocyte count; RSV, respiratory syncytial virus.
Figure 2Receiver operating characteristics (ROC) curve. Protective factors of severe infection (A). Risk factors of severe infection (B). Protective factors for poor prognosis of severe infection (C). Risk factors for poor prognosis of severe infection (D).
Univariate analysis of risk factors for poor prognosis of SIG in children with INS.
| WBC (×109/L) | 12.75 (8.98, 15.99) | 39 | 21.20 (15.78, 30.96) | 5 | 0.013 | |
| PLT (×109/L) | 366 (298, 499) | 39 | 155 (91, 461) | 5 | 0.134 | |
| Hb (g/L) | 126 (106, 145) | 39 | 80 (68, 125) | 5 | 0.046 | |
| ALC (×109/L) | 2.36 (1.57, 3.43) | 39 | 2.47 (1.38, 4.43) | 5 | 0.767 | |
| ANC (×109/L) | 9.27 (5.18, 11.39) | 39 | 12.21 (10.84, 20.15) | 5 | 0.042 | |
| CRP ≥ 8 mg/L ( | 17 (43.6%) | 39 | 4 (80.0%) | 5 | 0.176 | |
| PCT (ng/ml) | 0.43 (0.10, 8.65) | 39 | 5.52 (0.62, 45.64) | 5 | 0.155 | |
| Serum albumin (g/L) | 17.06 (14.30, 23.80) | 39 | 12.60 (10.20, 15.35) | 5 | 0.303 | |
| ALT (U/L) | 25.10 (15.10, 28.50) | 39 | 13.40 (9.75, 67.75) | 5 | 0.008 | |
| AST (U/L) | 31.20 (25.40, 46.50) | 39 | 22.10 (18.65, 242.05) | 5 | 0.015 | |
| ALP (U/L) | 102.60 (81.20, 137.50) | 39 | 78.00 (63.05, 164.50) | 5 | 0.275 | |
| Serum uric acid (μmol/L) | 346 (224, 485) | 39 | 360 (271, 449) | 5 | 0.853 | |
| Serum urea nitrogen (mmol/L) | 6.33 (3.70, 11.70) | 39 | 8.20 (5.67, 28.08) | 5 | 0.237 | |
| Serum creatinine (μmol/L) | 40.60 (27.00, 74.50) | 39 | 82.00 (37.00, 284.75) | 5 | 0.082 | |
| Serum potassium (mmol/L) | 4.11 ± 0.68 | 39 | 3.61 ± 1.04 | 5 | 0.157 | |
| Serum sodium (mmol/L) | 131.5 (129.2, 136.7) | 39 | 132.4 (122.0, 141.0) | 5 | 0.897 | |
| Serum chlorine (mmol/L) | 101.9 (96.0, 104.1) | 39 | 109.6 (101.1, 114.6) | 5 | 0.025 | |
| Serum calcium (mmol/L) | 1.91 (1.75, 2.09) | 39 | 1.67 (1.29, 1.78) | 5 | 0.009 | |
| Tch (mmol/L) | 9.24 ± 3.62 | 39 | 8.36 ± 2.69 | 5 | 0.607 | |
| Triglyceride (mmol/L) | 3.10 (2.38, 3.86) | 39 | 3.73 (3.05, 10.27) | 5 | 0.267 | |
| LDL (mmol/L) | 5.89 ± 3.30 | 39 | 5.05 ± 3.10 | 5 | 0.591 | |
| HDL (mmol/L) | 1.53 (0.94, 2.04) | 39 | 0.81 (0.56, 1.33) | 5 | 0.054 | |
| IgG (g/L) | 2.06 (0.96, 4.02) | 39 | 0.66 (0.51, 0.86) | 5 | 0.008 | |
| IgA (g/L) | 0.91 (0.66, 1.31) | 39 | 0.48 (0.40, 0.62) | 5 | 0.010 | |
| IgM (g/L) | 1.48 (1.08, 2.51) | 39 | 1.74 (0.82, 1.85) | 5 | 0.631 | |
| IgE (g/L) | 81.30 (21.30, 410.00) | 39 | 32.20 (27.66, 187.95) | 5 | 0.427 | |
| C3 (g/L) | 0.88 ± 0.30 | 39 | 0.63 ± 0.09 | 5 | 0.001 | |
| C4 (g/L) | 0.22 (0.16, 0.27) | 39 | 0.25 (0.23, 0.26) | 5 | 0.326 | |
| PT (s) | 11.05 (10.18, 12.83) | 39 | 11.20 (10.00, 13.20) | 5 | 0.909 | |
| APTT (s) | 36.30 (26.78, 53.83) | 39 | 37.50 (32.40, 44.20) | 5 | 0.791 | |
| Fib (g/L) | 5.56 ± 1.97 | 39 | 5.22 ± 1.99 | 5 | 0.714 | |
| D-dimer | 1.44 (0.55, 3.20) | 39 | 3.10 (0.86, 32.25) | 5 | 0.256 | |
p < 0.05,
p < 0.01.
Fisher exact method.
Continuous parameters were expressed as (X̄ ± s) or P50 (P25, P75), and discrete parameters were expressed as a percentage (%). SIG, severe infection group; WBC, white blood cells; ALC, absolute lymphocyte count; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelets count; CRP, C-reactive protein; PCT, procalcitonin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; Tch, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; PT, prothrombin time; APTT, activated partial thromboplastin time; Fib, fibrinogen.